Automera
Singapore- and Seattle-based biotechnology company founded in 2022 and launched with $16M in Series A commitments; it pioneers autophagy-driven targeted protein degradation, designing chimeric small molecules (AUTACs) with dual-binding capability using computational chemistry, AI and quantum molecular dynamics, with oncology as the initial lead program.
Headquarters
Singapore / Seattle, USA
Year Founded
2022
Founders
Taiyang Zhang, Loong Wang, Michael Lazarou
Country
Singapore
Financial Information
Funding Stage
Series A
Recent Funding
$16M
Funding By
Accelerator Life Science Partners (ALSP), ClavystBio, EDBI, Xora Innovation
Core Technology
AUTACs (autophagy-targeting chimeras) designed with AI and quantum molecular dynamics
Product Type
Drug
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: No
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Building IP portfolio
Partnerships
Pharma Collaborations
None disclosed
Academic / Hospital Tie-ups
Not disclosed
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
Degrades proteins through autophagy, reaching targets beyond the ubiquitin-proteasome system